Consequently, SG activity has been investigated also in this BC subtype, with encouraging outcomes coming from the HR+/HER2- metastatic BC cohort of the IMMU-132-01 (NCT01631552) basket trial [9]. This evidence concerns the gene ERBB2 and breast cancer.